A Complement-dependent Balance Between Hepatic Ischemia/reperfusion Injury and Liver Regeneration in Mice
Overview
Affiliations
Massive liver resection and small-for-size liver transplantation pose a therapeutic challenge, due to increased susceptibility of the remnant/graft to ischemia reperfusion injury (IRI) and impaired regeneration. We investigated the dual role of complement in IRI versus regeneration in mice. Complement component 3 (C3) deficiency and complement inhibition with complement receptor 2-complement receptor 1-related protein y (CR2-Crry, an inhibitor of C3 activation) provided protection from hepatic IRI, and while C3 deficiency also impaired liver regeneration following partial hepatectomy (PHx), the effect of CR2-Crry in this context was dose dependent. In a combined model of IRI and PHx, either C3 deficiency or high-dose CR2-Crry resulted in steatosis, severe hepatic injury, and high mortality, whereas low-dose CR2-Crry was protective and actually increased hepatic proliferative responses relative to control mice. Reconstitution experiments revealed an important role for the C3a degradation product acylation-stimulating protein (ASP) in the balance between inflammation/injury versus regeneration. Furthermore, liver regeneration was dependent on the putative ASP receptor, C5L2. Several potential mechanisms of hepatoprotection and recovery were identified in mice treated with low-dose CR2-Crry, including enhanced IL-6 expression and STAT3 activation, reduced hepatic ATP depletion, and attenuated oxidative stress. These data indicate that a threshold of complement activation, involving ASP and C5L2, promotes liver regeneration and suggest a balance between complement-dependent injury and regeneration.
Vandendriessche S, Mattos M, Bialek E, Schuermans S, Proost P, Marques P Front Immunol. 2025; 15:1512470.
PMID: 39759517 PMC: 11696981. DOI: 10.3389/fimmu.2024.1512470.
Saleh A, Mohamed A, Elnesr S, Khafaga A, Elwan H, Abdel-Aziz M Int J Mol Sci. 2024; 25(23).
PMID: 39684540 PMC: 11641086. DOI: 10.3390/ijms252312829.
Li Y, Horst K, Greven J, Mert U, Lupu L, Palmer A Front Immunol. 2024; 15:1434274.
PMID: 39640261 PMC: 11617561. DOI: 10.3389/fimmu.2024.1434274.
Yu S, King E, Fribourg M, Hartzell S, Tsou L, Gee L Am J Pathol. 2024; 195(1):126-142.
PMID: 39427763 PMC: 11686444. DOI: 10.1016/j.ajpath.2024.10.003.
Yang Z, Li C, Wang Y, Dong W, Yang M, Jin J J Cell Mol Med. 2024; 28(8):e18291.
PMID: 38597412 PMC: 11005456. DOI: 10.1111/jcmm.18291.